Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous
Journal of General Internal MedicinePublished 29 September 2005Open access
Christianne L. Roumie, Patrick G. Arbogast, Edward F. Mitchel, Marie R. Griffin
Citations21
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A substantial portion of coxib prescriptions were for a month’s supply at doses above those recommended for most chronic indications, and new users were also prescribed high doses despite evidence for cardiovascular comorbidity.
Abstract
A substantial portion of coxib prescriptions were for a month's supply at doses above those recommended for most chronic indications. New users were also prescribed high doses despite evidence for cardiovascular comorbidity. These prescribing patterns at doses outside licensed indications are both inappropriate and potentially dangerous.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
JAMARisks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
15,680 Citations2002Jacques E. Rossouw
Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
The LancetAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
10,121 Citations2002Sarah Lewington, Robert Clarke +3 more
Throughout middle and old age, usual blood pressure is strongly and directly related to vascular (and overall) mortality, without any evidence of a threshold down to at least 115/75 mm Hg.
New England Journal of MedicineThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
8,985 Citations1999Bertram Pitt, Faı̈ez Zannad +6 more
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
JAMARandomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
6,229 Citations1998Stephen B. Hulley
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
New England Journal of MedicineComparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
4,017 Citations2000Claire Bombardier, Loren Laine +10 more
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Survey of AnesthesiologyThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
2,936 Citations2000Bertram Pitt, Faı̈ez Zannad +6 more
New England Journal of MedicineCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
2,487 Citations2005Robert S. Bresalier, Robert S. Sandler +10 more
Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups.
New England Journal of MedicineCardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
2,054 Citations2005Scott D. Solomon, John J.V. McMurray +8 more
JAMARisk of Cardiovascular Events Associated With Selective COX-2 Inhibitors
1,742 Citations2001Debabrata Mukherjee
The results from VIGOR showed that the relative risk of developing a confirmed adjudicated thrombotic cardiovascular event with rofecoxib treatment compared with naproxen was higher than that in the placebo group of a recent meta-analysis of 23 407 patients in primary prevention trials.
New England Journal of MedicineComplications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
1,094 Citations2005Nancy A. Nussmeier, Andrew Whelton +6 more
The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances.
New England Journal of MedicineCoxibs and Cardiovascular Disease
893 Citations2004Garret A. FitzGerald
The coxibs are a subclass of nonsteroidal antiinflammatory drugs (NSAIDs) designed to inhibit selectively cyclooxygenase-2 (COX-2), which is the source of prostaglandins E2 and I2, which mediate inflammation.
JAMAAnti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis
804 Citations1999Lee S. Simon, Arthur L. Weaver +9 more
All dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen.
New England Journal of MedicineFailing the Public Health — Rofecoxib, Merck, and the FDA
589 Citations2004Eric J. Topol
On September 30, 2004, after more than 80 million patients had taken rofecoxib and annual sales had topped $2.5 billion, the company withdrew the drug because of an excess risk of myocardial infarctions and strokes.
The LancetCOX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
508 Citations2002Wayne A. Ray, Christoph Stein +4 more
A retrospective cohort study of individuals on the expanded Tennessee Medicaid programme (TennCare), in which occurrence of serious coronary heart disease (CHD) in non-users and in users of rofecoxib and other NSAIDs is assessed.
CirculationRelationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults
506 Citations2004Daniel H. Solomon, Sebastian Schneeweiß +5 more
Current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use, and Dosages of rofECoxib >25 mg were associated with a higher risk than dosages ≤25 mg, which was elevated in the first 90 days of use but not thereafter.
Annals of Internal MedicineNonsteroidal Anti-Inflammatory Drug Use and Death from Peptic Ulcer in Elderly Persons
422 Citations1988Marie R. Griffin, Wayne A. Ray +1 more
The findings of this study add to the growing evidence that NSAIDs can increase the risk for clinically serious peptic ulcer disease in the elderly.
Journal of Thoracic and Cardiovascular SurgeryEfficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery
403 Citations2003Elisabeth Ott, Nancy A. Nussmeier +8 more
In patients undergoing coronary artery bypass grafting surgery, the cyclooxygenase 2 inhibitor combination, parecoxib/valdecoxib, was effective for postoperative analgesia, however, the 14-day treatment regimen also was associated with an increased incidence of serious adverse events overall and sternal wound infections in particular.
Clinical TherapeuticsThe safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
137 Citations1999Thomas J. Schnitzer, K. E. Truitt +7 more
This 8-week, double-masked, placebo-controlled trial was undertaken to assess the safety profile, tolerability, and effective dose range of once-daily rofecoxib, a COX-2-specific inhibitor, in the treatment of rheumatoid arthritis and shows that rofECoxib 25 and 50 mg once daily was effective and generally well-tolerated in patients with RA.
Medical CareMedicaid Records as a Valid Data Source; The Tennessee Experience
64 Citations1976Charles F. Federspiel, Wayne A. Ray +1 more
Evaluation of the Medicaid claims processing system suggests other applications in health care administration and research, and the incisive use of Medicaid claims files offers an attractive alternative to expensive new systems of data collection and analysis.
Pharmacoepidemiology and Drug SafetyHigh frequency of use of rofecoxib at greater than recommended doses: cause for concern
19 Citations2003Marie R. Griffin, C. Michael Stein +4 more
Chronic use of high doses of rofecoxib has implications for patient safety, and in clinical trials of chronic use for arthritis, hypertension was more frequent in patients assigned 50 mg roficoxib than in those assigned lower doses or other NSAIDs.
PubMedComparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
18 Citations2002Sean Z. Zhao, Thomas Burke +3 more
COX-2-specific inhibitors were prescribed preferentially to patients who, at the time of their index COX- 2-specific inhibitor prescription, were at an increased baseline risk of CV events compared with patients prescribed nonspecific NSAIDs.
Journal of Vascular SurgeryComplications of the COX-II inhibitors parecoxib and valdecoxib after cardiac surgery
5 Citations2005NANCY A. NUSSMEIER, A.A. Whelton +1 more